Tsfg LLC Buys 6,784 Shares of Abbott Laboratories $ABT

Tsfg LLC lifted its stake in Abbott Laboratories (NYSE:ABT) by 6.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 114,037 shares of the healthcare product maker’s stock after purchasing an additional 6,784 shares during the period. Abbott Laboratories makes up 2.4% of Tsfg LLC’s investment portfolio, making the stock its 9th largest holding. Tsfg LLC’s holdings in Abbott Laboratories were worth $15,274,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Charles Schwab Trust Co raised its holdings in Abbott Laboratories by 109.8% during the third quarter. Charles Schwab Trust Co now owns 29,412 shares of the healthcare product maker’s stock worth $3,939,000 after purchasing an additional 15,394 shares during the last quarter. Asset Management One Co. Ltd. increased its position in shares of Abbott Laboratories by 2.4% in the third quarter. Asset Management One Co. Ltd. now owns 858,834 shares of the healthcare product maker’s stock valued at $115,032,000 after buying an additional 19,966 shares in the last quarter. Nordea Investment Management AB raised its stake in shares of Abbott Laboratories by 6.1% during the 3rd quarter. Nordea Investment Management AB now owns 329,430 shares of the healthcare product maker’s stock worth $43,785,000 after buying an additional 18,974 shares during the last quarter. AE Wealth Management LLC boosted its position in shares of Abbott Laboratories by 20.8% in the 3rd quarter. AE Wealth Management LLC now owns 65,504 shares of the healthcare product maker’s stock worth $8,774,000 after buying an additional 11,264 shares in the last quarter. Finally, Seaview Investment Managers LLC acquired a new stake in Abbott Laboratories in the 2nd quarter valued at about $11,068,000. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Abbott Laboratories Trading Up 0.2%

NYSE:ABT opened at $109.51 on Tuesday. Abbott Laboratories has a 12 month low of $105.27 and a 12 month high of $141.23. The company has a current ratio of 1.70, a quick ratio of 1.24 and a debt-to-equity ratio of 0.23. The stock has a market capitalization of $190.43 billion, a price-to-earnings ratio of 29.44, a PEG ratio of 1.74 and a beta of 0.75. The firm has a fifty day simple moving average of $122.41 and a two-hundred day simple moving average of $127.35.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.50. The company had revenue of $11.46 billion for the quarter, compared to analysts’ expectations of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.94%. The business’s revenue was up 4.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.34 EPS. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Analysts expect that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, February 13th. Investors of record on Thursday, January 15th will be given a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 2.3%. The ex-dividend date of this dividend is Thursday, January 15th. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.59. Abbott Laboratories’s payout ratio is 67.74%.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott’s CEO personally invested roughly $2M while the stock has been under pressure — a management buy that signals confidence to shareholders and can help stabilize sentiment. Article Title
• Positive Sentiment: Freedom Capital upgraded ABT to a Buy (recently lowering its PT to $120), which gives the stock a retail/institutional buying narrative despite the lower target. Article Title
• Positive Sentiment: Long‑term bull case pieces note Abbott’s Dividend Aristocrat status, multi‑year revenue growth and strong balance sheet, reinforcing a buy-and-hold thesis for income/quality investors. Article Title
• Positive Sentiment: Opinion/bull-case coverage outlines structural upside from diagnostics and recurring revenue streams, offering a narrative that could attract growth‑oriented buyers. Article Title
• Neutral Sentiment: Abbott’s deal with Exact Sciences is reshaping its diagnostics footprint (strategic upside), but its nutrition business is undergoing a reset — a mixed development that likely means longer lead times before clear earnings upside. Article Title
• Neutral Sentiment: Barclays trimmed its price target from $169 to $142 but kept an Overweight rating, signaling conviction in Abbott’s story despite near-term headwinds. Article Title
• Neutral Sentiment: Valuation comparisons (e.g., Zacks piece on NVST vs ABT) highlight Abbott as a relatively lower-volatility, dividend-oriented option — useful context but not an immediate catalyst. Article Title
• Negative Sentiment: Daiwa cut its price target to $113 — a downgrade that adds selling pressure from analysts and may weigh on near‑term sentiment. Article Title
• Negative Sentiment: Leerink lowered its target to $119, another analyst haircut that contributes to a chorus of reduced near‑term expectations. Article Title

Analyst Upgrades and Downgrades

Several research firms have recently commented on ABT. Barclays lowered their price target on shares of Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating on the stock in a research report on Monday. Sanford C. Bernstein decreased their price objective on shares of Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. BTIG Research lowered their target price on shares of Abbott Laboratories from $145.00 to $140.00 and set a “buy” rating for the company in a research note on Friday, January 23rd. Oppenheimer cut their price target on shares of Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Finally, Raymond James Financial lowered their price objective on Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $137.05.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.